WO2009067607A3 - Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders - Google Patents

Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders Download PDF

Info

Publication number
WO2009067607A3
WO2009067607A3 PCT/US2008/084207 US2008084207W WO2009067607A3 WO 2009067607 A3 WO2009067607 A3 WO 2009067607A3 US 2008084207 W US2008084207 W US 2008084207W WO 2009067607 A3 WO2009067607 A3 WO 2009067607A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
amount
antipsychotics
combinations
psychotic disorders
Prior art date
Application number
PCT/US2008/084207
Other languages
French (fr)
Other versions
WO2009067607A2 (en
Inventor
David A Lowe
Original Assignee
Memory Pharm Corp
David A Lowe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp, David A Lowe filed Critical Memory Pharm Corp
Publication of WO2009067607A2 publication Critical patent/WO2009067607A2/en
Publication of WO2009067607A3 publication Critical patent/WO2009067607A3/en
Priority to IL205680A priority Critical patent/IL205680A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods and compositions for treating a psychotic disorder or condition, associated with cognitive impairment. The pharmaceutical composition comprises: (a) an amount of an antipsychotic agent and (b) an amount of a PDE4 inhibitor compound, wherein the amounts of (a) and (b) are together effective in treating the cognitive impairment or psychotic disorder such as schizophrenia. The method of treatment comprises administering to a patient (a) an amount of a antipsychotic agent and (b) an amount of a PDE4 inhibitor compound, wherein the amounts of (a) and (b) are together effective in treating the psychotic disorder such as schizophrenia.
PCT/US2008/084207 2007-11-20 2008-11-20 Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders WO2009067607A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL205680A IL205680A0 (en) 2007-11-20 2010-05-11 Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98922107P 2007-11-20 2007-11-20
US60/989,221 2007-11-20

Publications (2)

Publication Number Publication Date
WO2009067607A2 WO2009067607A2 (en) 2009-05-28
WO2009067607A3 true WO2009067607A3 (en) 2009-08-13

Family

ID=40668089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/084207 WO2009067607A2 (en) 2007-11-20 2008-11-20 Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders

Country Status (2)

Country Link
IL (1) IL205680A0 (en)
WO (1) WO2009067607A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
EP3016951B1 (en) 2013-07-02 2017-05-31 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
ES2634628T3 (en) 2013-07-02 2017-09-28 Bristol-Myers Squibb Company Tricyclic derivatives of pyrido-carboxamide as ROCK inhibitors
EP4144736A1 (en) 2015-04-29 2023-03-08 JANSSEN Pharmaceutica NV Azabenzimidazoles and their use as ampa receptor modulators
EP3288945B1 (en) * 2015-04-29 2019-09-18 Janssen Pharmaceutica NV Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
JOP20190126A1 (en) * 2016-12-22 2019-05-28 H Lundbeck As Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US20040204401A1 (en) * 2002-07-30 2004-10-14 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US6974837B2 (en) * 1999-08-11 2005-12-13 Sepracor Inc. Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
US7087625B2 (en) * 2002-11-19 2006-08-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7235579B2 (en) * 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974837B2 (en) * 1999-08-11 2005-12-13 Sepracor Inc. Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7235579B2 (en) * 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US20040204401A1 (en) * 2002-07-30 2004-10-14 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US7087625B2 (en) * 2002-11-19 2006-08-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANES, S. J. ET AL.: "Rolipram: a specifie phosphodiesterase 4 inhibitor with potential antipsychotic activity", NEUROSCIENCE, vol. 144, no. 1, 5 January 2007 (2007-01-05), pages 239 - 46, XP005793708 *

Also Published As

Publication number Publication date
IL205680A0 (en) 2010-11-30
WO2009067607A2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
WO2008033562A3 (en) Kinase inhibitor compounds
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
PT2383271E (en) Aminoquinolones as gsk-3 inhibitors
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
EP1924293A4 (en) Composition and method for prevention and treatment of type i diabetes
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
WO2007092622A3 (en) Compositions and methods for treating bone
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2009027346A3 (en) 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
IL195030A (en) Dpp iv inhibitor formulations
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2008039829A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
WO2008030883A3 (en) Treatment of cancer
BRPI0508254A (en) methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
EP2331093A4 (en) Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
WO2007145704A3 (en) Gemcitabine combination therapy
MX2009012920A (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome.
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2010059004A3 (en) Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
WO2009067607A3 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08852058

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 205680

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008852058

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE